Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Peijia Medical Secures Exclusive China Distribution Rights for B. Braun’s SeQuent Please CIS Intracranial Drug-Coated Balloon

Fineline Cube Jun 1, 2026
Company Deals

Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement

Fineline Cube Jun 1, 2026
Company Deals

True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations

Fineline Cube Jun 1, 2026
Company Deals

Sihuan Pharmaceutical and dProtein Biotechnology Form AI-Powered Medical Aesthetics Joint Venture

Fineline Cube May 29, 2026
Company Deals Drug

Salvectors Receives NMPA Clinical Approval for YB1-X7, World’s First Oncolytic Salmonella Therapy for Advanced Solid Tumors

Fineline Cube May 29, 2026
Policy / Regulatory

NMPA Opens 2026 National Reimbursement Drug List Application Window with Revised Eligibility Criteria and Price Controls

Fineline Cube Jun 1, 2026
Company Drug

BMS Secures EC Approval for Opdivo-AVD Combination in Advanced Classical Hodgkin Lymphoma

Fineline Cube Jun 2, 2026
Company Drug

D3 Bio’s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026

Fineline Cube Jun 1, 2026
Company Drug

MSD MK-2214 Fast Track Alzheimer Data Positive

Fineline Cube Dec 3, 2025

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) released first‑in‑human data for MK-2214 and MK-1167 in...

Policy / Regulatory

China Drug-Price Registration System Launches with First Batch of 10 Products

Fineline Cube Dec 3, 2025

China’s Drug Price Registration System officially launched today with the first batch of 10 drug...

Company Deals

3SBio HK$3.1B Placement Funds R&D Pipeline for 705, 706, 008

Fineline Cube Dec 3, 2025

3SBio Inc. (HKG: 1530) conditionally agreed to place 105,169,500 shares at HK$29.62 per share, raising...

Company Drug

Generate GB-0895 Asthma Phase III Trials to Enroll 1,600 Patients

Fineline Cube Dec 3, 2025

Generate: Biomedicines today announced plans to initiate two global Phase III clinical trials (SOLAIRIA-1 and...

Company Drug

Henlius HLX14 Denosumab Biosimilar NDA Accepted by China CDE

Fineline Cube Dec 3, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the National Medical Products Administration’s Center for...

Company Deals

New-Radiomedicine Series-D Raises 800M Yuan for Radiopharmaceuticals

Fineline Cube Dec 3, 2025

Chengdu New Radiomedicine Technology Co., Ltd. announced completion of its Series D financing round, raising...

Company Deals Drug

Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment

Fineline Cube Dec 3, 2025

Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI...

Company Medical Device

Roche cobas-liat Whooping-Cough Test Secures FDA Clearance

Fineline Cube Dec 3, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its cobas liat system-based point‑of‑care test for whooping...

Company Drug

Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors

Fineline Cube Dec 2, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant...

Company Drug

Leads-Biolabs LBL047 Bispecific Secures China IND Approval for SLE

Fineline Cube Dec 2, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that the National Medical Products Administration (NMPA)...

Company Deals

Shanghai Bao Pharma IPO HKEX Raises HK$1 Billion for Biotech Pipeline

Fineline Cube Dec 2, 2025

Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) successfully listed on the Hong Kong Stock Exchange...

Company Drug

Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval

Fineline Cube Dec 2, 2025

Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141,...

Company Drug

AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China

Fineline Cube Dec 2, 2025

AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list...

Company Drug

Lynk Pharma LNK01006 FDA Approval Targets TYK2 for CNS Diseases

Fineline Cube Dec 2, 2025

Lynk Pharmaceuticals Co., Ltd. announced that its self‑developed TYK2 allosteric inhibitor LNK01006 has received FDA...

Others

FDA Prasad Outlines New Vaccine Approval Process After Covid-19 Safety Analysis

Fineline Cube Dec 2, 2025

Dr. Vinay Prasad, FDA’s chief medical and scientific officer, announced plans to overhaul the vaccine...

Hospital Policy / Regulatory

China Health: Life Expectancy Hits 79 Years as Hospitals Expand and Expenditure Controlled

Fineline Cube Dec 2, 2025

The National Health Commission released the Statistical Bulletin on China’s Health Undertakings 2024, showing China’s...

Company Drug

CANbridge’s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus

Fineline Cube Dec 2, 2025

CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of...

Company Deals

WuXi Biologics CRDMO Qatar MOU Establishes First Middle East Center

Fineline Cube Dec 2, 2025

WuXi Biologics (HKG: 2269) announced it has signed a strategic Memorandum of Understanding (MOU) with...

Company Drug

Johnson & Johnson’s Nipocalimab Secures EU Approval for Myasthenia Gravis

Fineline Cube Dec 2, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission has granted Marketing Authorisation...

Company Deals

Regeneron Tessera Partner on TSRA-196 Gene-Writing Therapy for AATD with $275M Deal

Fineline Cube Dec 2, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Tessera Therapeutics announced a global collaboration to develop and...

Posts pagination

1 … 82 83 84 … 675

Recent updates

  • BMS Secures EC Approval for Opdivo-AVD Combination in Advanced Classical Hodgkin Lymphoma
  • D3 Bio’s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026
  • Impact Therapeutics’ Selective PARP1 Inhibitor IMP1734 Shows 29.6% Response Rate in Ovarian Cancer at ASCO 2026
  • CTTQ’s EGFR/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026
  • GenFleet’s GFS202A Becomes World’s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BMS Secures EC Approval for Opdivo-AVD Combination in Advanced Classical Hodgkin Lymphoma

Company Drug

D3 Bio’s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026

Company Drug

Impact Therapeutics’ Selective PARP1 Inhibitor IMP1734 Shows 29.6% Response Rate in Ovarian Cancer at ASCO 2026

Company Drug

CTTQ’s EGFR/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.